Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2CLIMB-02: Tucatinib plus T-DM1 in unresectable locally-advanced or metastatic HER2+ breast cancer
2024-514733-38-00Phase 3Authorised
- Sponsor
- Seagen Inc.
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Tucatinib + T-DM1 with Placebo + T-DM1 (2 arms). Primary endpoint: Progression-free survival (PFS). Planned start Jul 2024; status: authorised.
02
Drugs
tucatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-514733-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514733-38-00.